Stock Report

All about this stock under one free report Last Updated: 29-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Parmax Pharma Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

BSE: 540359

₹131.15

up-down-arrow ₹1.25 (0.96%)

As on 24-Aug-2026IST

Market cap

info icon

₹49 Cr

Revenue (TTM)

info icon

₹18 Cr

P/E Ratio

info icon

--

P/B Ratio

info icon

-10.5

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 148.14 323.33 21.10 6.40 -6.45
EBIT 119.39 170.93 -111.89 -290.94 -213.08
Net Profit 477.19 387.45 51.58 -418.28 -197.97
EPS 477.19 387.45 64.45 -418.29 -197.97
Book Value -- -- -346.39 -184.59 -199.48
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-25Mar-24
EBIT-Margin info -15.42-7.44-20.44-2.76-45.97
Net Margin info -19.96-11.25-5.82-7.41-51.80
Return on equity info -93.23-50.75--0.00-277.44
Return on Capital info -28.56-12.56---29.88-59.76
Return on Assets info -15.95-8.74-5.10-12.36-34.91
Debt to Equity (x) info -----1.87-4.0756.07

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
--
-29.88
-59.76
3.96
6.62
Peer Median
--
30.15
25.60
28.10
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

--

--

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
--
--
-277.44
-2.26
3.38
Peer Median
19.47
22.45
20.46
22.84
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-5.10

Lower than Peers by 18.47

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
-5.10
-12.36
-34.91
-0.58
0.70
Peer Median
13.38
14.45
12.89
13.18
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-20.44

Lower than Peers by 35.81

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
-20.44
-2.76
-45.97
2.46
3.44
Peer Median
15.37
14.69
13.67
14.73
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-5.82

Lower than Peers by 17.58

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
-5.82
-7.41
-51.80
-0.67
0.77
Peer Median
11.76
10.45
10.62
10.46
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
0.00
-3.77
-36.54
11.50
11.36
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

21.10

Higher than Peers by 18.04

Year on year growth in net sales

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
21.10
155.17
-28.23
-15.57
-30.31
Peer Median
3.07
6.12
2.92
26.08
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-111.89

Lower than Peers by 120.35

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
-111.89
84.71
-1,438.89
-39.45
-57.49
Peer Median
8.45
-1.86
24.62
-2.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

51.58

Higher than Peers by 39.09

Year on year growth in profit after tax

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
51.58
63.59
-5,425.72
-173.54
-81.24
Peer Median
12.49
1.68
29.22
-3.56
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

64.45

Higher than Peers by 59.37

Year on year growth in earnings per share

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
64.45
63.59
-5,424.95
-173.56
-81.24
Peer Median
5.08
-4.71
32.56
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
--
-346.40
-112.73
6.55
13.72
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

-1.87

Lower than Peers by 1.87

Total debt / Net worth

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
-1.87
-4.07
56.07
0.98
1.00
Peer Median
0.00
0.05
0.06
0.06
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

0.74

Lower than Peers by 1.52

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
0.74
0.77
0.63
1.06
0.90
Peer Median
2.25
2.06
1.89
2.00
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.39

Lower than Peers by 1.25

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
0.39
0.51
0.37
0.45
0.51
Peer Median
1.64
1.76
1.37
1.04
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-1.32

Lower than Peers by 32.88

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
-1.32
-3.09
-8.08
1.12
1.78
Peer Median
31.56
36.81
37.17
39.35
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

17.20

Higher than Peers by 3.18

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
17.20
4.53
16.43
4.04
3.71
Peer Median
14.02
13.72
13.52
14.42
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.79

Lower than Peers by 0.30

Sales / Average Total Assets

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
0.79
1.66
0.67
0.87
0.90
Peer Median
1.08
1.12
1.27
1.37
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
--
20.01
40.27
15.38
23.31
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
--
36.94
110.64
84.70
68.05
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
--
149.20
311.96
338.42
419.72
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
--
-92.25
-161.05
-238.34
-328.36
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
--
--
--
--
108.00
Peer Median
47.41
55.67
50.55
59.69
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

-10.54

Lower than Peers by 18.44

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
-10.54
-5.86
-17.63
2.39
3.43
Peer Median
7.90
10.68
9.96
12.87
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
--
--
--
--
--
Peer Median
0.81
0.65
0.54
0.51
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-154.47

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
-154.47
80.88
-4.97
7.10
7.40
Peer Median
--
38.80
44.18
51.38
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

49

Lower than Peers by 57,633

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Parmax Pharma
49
16
11
11
15
Peer Median
57,682
65,716
53,574
56,479
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...